Craig Blain
@jcraigblain.bsky.social
Reposted by Craig Blain
Developmental Mutators: A unified theory of why young people develop cancer ☛ alexkentsis.net/lecture-deve...
Lecture: Developmental Mutators: A unified theory of why young people develop cancer - Kentsis Research Group at Memorial Sloan Kettering Cancer Center
Listen to my lecture at the St. Jude Science of Childhood Cancer Series
alexkentsis.net
September 23, 2025 at 10:42 PM
Developmental Mutators: A unified theory of why young people develop cancer ☛ alexkentsis.net/lecture-deve...
Reposted by Craig Blain
This is horrible to post, but I may as well post it. We are essentially shutting down research operations in my group, which is focused on treatments for pediatric brain cancer. I’m a well funded investigator, and there’s no choice. Science can’t function without the stability of NIH
March 15, 2025 at 5:32 PM
This is horrible to post, but I may as well post it. We are essentially shutting down research operations in my group, which is focused on treatments for pediatric brain cancer. I’m a well funded investigator, and there’s no choice. Science can’t function without the stability of NIH
Reposted by Craig Blain
NEW ODD LOTS:
Trump's NIH cuts send shockwaves through the science world
We talked to biologist Carolw Labonne about how research works, and what limits on indirect funding do to the process.
podcasts.apple.com/us/podcast/t...
Trump's NIH cuts send shockwaves through the science world
We talked to biologist Carolw Labonne about how research works, and what limits on indirect funding do to the process.
podcasts.apple.com/us/podcast/t...
Trump's NIH Cuts Send Shockwaves Through the Science World
Podcast Episode · Odd Lots · 03/08/2025 · 44m
podcasts.apple.com
March 8, 2025 at 5:35 PM
NEW ODD LOTS:
Trump's NIH cuts send shockwaves through the science world
We talked to biologist Carolw Labonne about how research works, and what limits on indirect funding do to the process.
podcasts.apple.com/us/podcast/t...
Trump's NIH cuts send shockwaves through the science world
We talked to biologist Carolw Labonne about how research works, and what limits on indirect funding do to the process.
podcasts.apple.com/us/podcast/t...
Reposted by Craig Blain
In today's Odd Lots Newsletter, i wrote about Walter Ong Thought, and how as we return to Orality, we're completely re-wiring the logic engine of the human brain.
Get the newsletter here: www.bloomberg.com/account/news...
Get the newsletter here: www.bloomberg.com/account/news...
February 7, 2025 at 4:07 PM
In today's Odd Lots Newsletter, i wrote about Walter Ong Thought, and how as we return to Orality, we're completely re-wiring the logic engine of the human brain.
Get the newsletter here: www.bloomberg.com/account/news...
Get the newsletter here: www.bloomberg.com/account/news...
Reposted by Craig Blain
I never tire of seeing these progressively improved pediatric ALL survival curves, which represent one of the most remarkable achievements in all of medicine.
Amazing to see even more improvement with bispecific antibody #immunotherapy presented in the #ASH24 Plenary session. #hematology #leukemia
Amazing to see even more improvement with bispecific antibody #immunotherapy presented in the #ASH24 Plenary session. #hematology #leukemia
December 8, 2024 at 10:16 PM
I never tire of seeing these progressively improved pediatric ALL survival curves, which represent one of the most remarkable achievements in all of medicine.
Amazing to see even more improvement with bispecific antibody #immunotherapy presented in the #ASH24 Plenary session. #hematology #leukemia
Amazing to see even more improvement with bispecific antibody #immunotherapy presented in the #ASH24 Plenary session. #hematology #leukemia
Reposted by Craig Blain
Good morning, friends. There is some Arrakis news. Please forgive the promotional content, but I'm super excited about what we've done here, knowing - feeling - how much sweat, talent, creativity, persistence, resilience, and orthogonal thinking it took to make this happen. So proud of this team.
Arrakis Therapeutics Unveils Data for its Lead, Rationally Designed, RNA-Targeted Small Molecule (rSM) Drug Program Demonstrating Disease-Modifying Binding to RNA to Treat Myotonic Dystrophy - Arrakis...
Preclinical data presented at Cell Symposia conference show a small molecule directed at a pathogenic RNA achieved reversal of myotonia in an animal model of myotonic dystrophy Type 1 (DM1) Supports a...
arrakistx.com
December 4, 2024 at 12:21 PM
Good morning, friends. There is some Arrakis news. Please forgive the promotional content, but I'm super excited about what we've done here, knowing - feeling - how much sweat, talent, creativity, persistence, resilience, and orthogonal thinking it took to make this happen. So proud of this team.
Reposted by Craig Blain
5 years ago, Arrakis announced progress on a chemist's dream: Drugging RNA instead of proteins.
The goal: Reach undruggable cancer targets, like myc
It's been a long and bumpy road since then, @gilman.bsky.social explains. But there's been progress
www.statnews.com/2024/12/04/a...
The goal: Reach undruggable cancer targets, like myc
It's been a long and bumpy road since then, @gilman.bsky.social explains. But there's been progress
www.statnews.com/2024/12/04/a...
Arrakis CEO cites ‘cul-de-sacs’ on road to RNA-intercepting cancer drugs
.@ArrakisTx was formed to create RNA-intercepting drugs to fight cancer. Despite some promising data, CEO @michael_gilman says it will shift targets.
www.statnews.com
December 4, 2024 at 12:49 PM
5 years ago, Arrakis announced progress on a chemist's dream: Drugging RNA instead of proteins.
The goal: Reach undruggable cancer targets, like myc
It's been a long and bumpy road since then, @gilman.bsky.social explains. But there's been progress
www.statnews.com/2024/12/04/a...
The goal: Reach undruggable cancer targets, like myc
It's been a long and bumpy road since then, @gilman.bsky.social explains. But there's been progress
www.statnews.com/2024/12/04/a...